88 results on '"Overbeck T"'
Search Results
2. Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC – treatment results after long-term follow-up and literature overview
3. CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC
4. Mitomycin C in combination with vinorelbine or cisplatin and erythropoietin in pretreated patients with in field relapse after radiation therapy of non-small cell lung cancer: a phase II trial of the AIO
5. Zweitlinientherapie des kleinzelligen Lungenkarzinoms (SCLC)
6. Detection of pulmonary nodules at spiral CT: comparison of maximum intensity projection sliding slabs and single-image reporting
7. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
8. Population Pharmacokinetics of Melphalan and Glutathione S-transferase Polymorphisms in Relation to Side Effects
9. Top level MET amplification : an unfavourable subgroup in non-small cell lung cancer patients
10. P2.04-005 GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC
11. PS04.06 GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC
12. Induction therapy with intercalated TKI and chemotherapy in NSCLC with activating EGFR mutation in stages II-IIIB: NeoIntercal
13. Expression Patterns of ABCA3 and TTF-1 in Non-Small Cell Lung Cancer
14. FDG-PET response predicts overall and disease free survival after induction chemotherapy of locally advanced (stage III) Non-Small Cell Lung Cancer (NSCLC)
15. Die FDG-PET nach Induktions-Chemotherapie ist ein prognostischer Faktor für das Gesamtüberleben und das krankheitsfreie Intervall: Ergebnisse einer Phase II-Induktions-Therapie mit Docetaxel und Carboplatin bei nichtkleinzelligen Lungenkarzinom
16. Molekulargenetische Untersuchungen bei fortgeschrittenem nicht-kleinzelligem Lungenkarzinom: praktische Relevanz
17. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
18. Sicherung der Ergebnisqualität. Zweitlinientherapie bei NSCLC
19. Beidseitiges Papillenödem
20. Inhibition of Airway Smooth Muscle (ASM) Remodeling by Mannan from Saccharomyces (S.) cerevisiae
21. Population Pharmacokinetics of Melphalan and Glutathione S-transferase Polymorphisms in Relation to Side Effects
22. C1-01: Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC)
23. Mitomycin (M) in combination with cisplatin (P) or vinorelbine (V) and erythropoietin (Epo) in patients with in field relapse after radiation therapy of non-small cell lung cancer: A phase II study of the AIO
24. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
25. FDG-PET response predicts overall and disease free survival after induction chemotherapy of locally advanced (stage III) Non-Small Cell Lung Cancer (NSCLC)
26. Is invasive staging of NSCLC with mediastinoscopy/VATS advantageous to CT scan and PET?
27. O-69a Phase II induction therapy with docetaxel and carboplatinin NSCLC IIIA/IIIB: FDG-PET response predicts overall and disease free survival
28. PD-152 Identification of patients potentially benefitting from concomitant EGF-R inhibition and chemotherapy: Challenge trial: Erlotinib followed by gemcitabine/cisplatin +/− erlotinib induction in patients with NSCLC IIIA (N2)/IIIB (N3) monitored by microarray-analyses
29. Phase II induction therapy with docetaxel and carboplatin in NSCLC IIIA/IIIB: FDG-PET response predicts overall and disease free survival
30. Pharmacokinetics of melphalan and genotypes of glutathione S-transferases GSTM1 and GSTT1 and correlation to adverse effects
31. Kostenminimierungsstudie zur definitiven Therapie der Hyperthyreose: Vergleich zwischen Strumaresektion und Radiojodtherapie
32. Ontogeny and effect of activity on proenkephalin mRNA expression during development of the chick spinal cord
33. Assessment of fetoplacental and uteroplacental blood flow using duplex pulsed Doppler ultrasound in complicated pregnancies.
34. Kostenminimierungsstudie zur definitiven Therapie der Hyperthyreose: Vergleich zwischen Strumaresektion und Radiojodtherapie
35. Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature
36. Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC).
37. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
38. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
39. Study protocol: a prospective single-center study for non-invasive biomonitoring of renal complications in cancer patients treated with immune checkpoint inhibitors.
40. Response of eosinophilic fasciitis associated with Waldenström macroglobulinemia to rituximab.
41. Leucaemia cutis bei einem Patienten mit chronischer myelomonozytärer Leukämie.
42. Leukemia cutis in a patient with chronic myelomonocytic leukemia.
43. Beneficial Effects of Prebiotic Saccharomyces cerevisiae Mannan on Allergic Asthma Mouse Models.
44. Fermentation of de-oiled algal biomass by Lactobacillus casei for production of lactic acid.
45. Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation.
46. [Molecular genetic tests in advanced non-small cell lung cancer: practical relevance].
47. [Tumor Conference I].
48. Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.
49. High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer.
50. High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.